Next Article in Journal
Macroscopic Synovial Inflammation Correlates with Symptoms and Cartilage Lesions in Patients Undergoing Arthroscopic Partial Meniscectomy: A Clinical Study
Next Article in Special Issue
Comparison of Corvis ST Parameters between Primary Open-Angle Glaucoma and Primary Angle-Closure Glaucoma
Previous Article in Journal
Case-Fatality and Temporal Trends in Patients with Psoriasis and End-Stage Renal Disease
Previous Article in Special Issue
Special Issue “Recommendations for Clinical Management of Glaucoma”
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 11
Issue 15
10.3390/jcm11154325
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis

by
Tzu-Chen Lo
1,2,3,
Yu-Yen Chen
3,4,5,6,7,*,
Man-Chen Hung
1,8 and
Pesus Chou
9
1
Department of Medical Education, Taichung Veterans General Hospital, Taichung 407, Taiwan
2
Department of Ophthalmology, Taipei Veterans General Hospital, Taipei 112, Taiwan
3
School of Medicine, National Yang-Ming University, Taipei 112, Taiwan
4
Department of Ophthalmology, Taichung Veterans General Hospital, Taichung 407, Taiwan
5
Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD 21287, USA
6
School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
7
Department of Post Baccalaureate Medicine, National Chung Hsing University, Taichung 402, Taiwan
8
School of Medicine, Mackay Medical College, New Taipei City 252, Taiwan
9
Institute of Public Health, National Yang-Ming University, Taipei 112, Taiwan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2022, 11(15), 4325; https://doi.org/10.3390/jcm11154325
Submission received: 12 May 2022 / Revised: 16 July 2022 / Accepted: 22 July 2022 / Published: 26 July 2022
(This article belongs to the Special Issue Recommendations for Clinical Management of Glaucoma)
Browse Figures
Review Reports Versions Notes

Abstract

:
Latanoprostene bunod (LBN) 0.024%, a newly approved glaucoma eye drop, is metabolized into latanoprost acid and a nitric oxide (NO)-donating moiety, thus increasing the outflow of aqueous humor through the uveoscleral and trabecular routes, respectively. This study aimed to evaluate the intraocular pressure (IOP)-lowering effect of LBN among patients with open-angle glaucoma (OAG) and ocular hypertension (OHT). The effectiveness of LBN was also compared with timolol maleate 0.5% and latanoprost 0.005%. We searched PubMed and Embase between 1 January 2010, and 31 March 2022 and adopted only peer-reviewed clinical studies in our meta-analysis. A total of nine studies (2389 patients with OAG or OHT) assessing the IOP-reduction effect of LBN were included. Standardized mean differences (SMDs) of IOP between post-treatment time points (2 weeks, 6 weeks, 3 months, 6 months, 9 months, and 12 months) and baseline were calculated. The pooled analysis according to each time point revealed a significant IOP drop after LBN treatment (all p values for SMD < 0.05). In addition, LBN revealed a significantly stronger efficacy in decreasing IOP than timolol maleate 0.5% and latanoprost 0.005% during the follow-up period of three months. No serious side effects of LBN 0.024% were reported. Our study concluded that LBN could achieve good performance for IOP reduction in patients with OAG and OHT. The safety was favorable with no severe side effects.

1. Introduction

Glaucoma is the leading cause of irreversible blindness [1]. Lowering the intraocular pressure (IOP) can slow optic nerve injury and visual field deterioration and is thus a proven effective treatment [1,2]. To this end, clinicians have relied on glaucoma eye drops as a means to either reduce aqueous humor production or increase aqueous humor outflow facilities through trabecular meshwork or uveoscleral routes [3]. Beta-blockers, cholinergic agents, carbonic anhydrase inhibitors, alpha-adrenergic receptor agonists, and prostaglandin analogs have remained the standard of care for over 20 years.
Li et al. revealed that prostaglandin analogs (e.g., latanoprost 0.005%) and beta-blockers (e.g., timolol maleate 0.5%) are among the most efficacious categories of glaucoma eye drops in reducing IOP [4]. Although these therapies certainly have a positive impact, they are insufficient at hindering disease progression in 30–80% of glaucoma patients [2,5]. Therefore, medications with novel mechanisms of action are needed.
Latanoprostene bunod (LBN) 0.024% is a new IOP-lowering eye drop approved by the US Food and Drug Administration (FDA) in November 2017. LBN is a nitric oxide (NO)-donating prostaglandin F2α analog that, when applied to the ocular surface, is rapidly metabolized into latanoprost acid and a NO-donating moiety, butanediol mononitrate [6,7]. Latanoprost acid reduces IOP by increasing uveoscleral outflow, whereas NO facilitates trabecular outflow through relaxation of the trabecular meshwork and Schlemm’s canal [8].
Randomized controlled trials (RCTs), such as APOLLO, JUPITER, LUNAR, VOYAGER, and CONSTELLATION, as well as a pooled study conducted by Weinreb et al., have assessed the IOP-reduction effect of LBN in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT) [9,10,11,12,13,14]. Since the approval of LBN, retrospective studies (e.g., chart reviews) regarding its IOP-lowering effect in the real-world setting have been performed [15,16,17]. To ensure a complete understanding of LBN 0.024%, we investigated its efficacy in decreasing IOP in both the RCTs and retrospective studies. In this meta-analysis, we aimed to evaluate the impact of LBN 0.024% on IOP, which was further compared with timolol maleate 0.5% and latanoprost 0.005%. The adverse effects of LBN 0.024% were also recorded for a safety assessment.

2. Materials and Methods

2.1. Search Strategy

This study was conducted in accordance with the Preferred Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We performed a literature search in the PubMed and Embase databases for studies published from 1 January 2010 to 31 March 2022 using the keyword ‘latanoprostene bunod’. Papers were initially screened by examining the titles and abstracts. Then, the full texts were further assessed to determine whether the studies met the inclusion criteria. Bibliographies were also manually searched for the relevant literature.

2.2. Inclusion and Exclusion Criteria

We included only peer-reviewed journal articles written in English. Only original prospective studies or retrospective clinical studies were included. Studies met the following inclusion criteria: (1) study population of OAG or OHT patients; (2) a clear definition of the study design as well as the doses and frequency of eye drops; and (3) analysis of the effect of IOP lowering in LBN with or without comparison to timolol maleate 0.5% or latanoprost 0.005%. It was also noteworthy that patients included were either naive to glaucoma eye drops or had undergone a washout period to ensure that the previous prescription did not influence the effect of the study eye drop. Reviews, meta-analyses, and conference abstracts were excluded due to the inclusion of repeated cases. Two researchers (Lo and Chen) independently assessed the eligibility of these articles. Discordances were resolved by a third reviewer (Hung).

2.3. Extraction of Variables

The following data were recorded from the included articles: the first author, the year of publication, country, study design, glaucoma eye drops, total number of patients, total number of study eyes, age (mean and standard deviation) and sex distribution of participants, baseline IOP, and post-treatment IOP at each time point (1 week, 2 weeks, 6 weeks, 3 months, 6 months, 9 months, and 12 months). The adverse effects of LBN 0.024% were also listed and summarized.

2.4. Statistical Analysis

Comprehensive Meta-Analysis software, version 3 (Biostat, Englewood, NJ, USA) was used for the statistical analysis. The mean IOP reduction in the LBN at each post-treatment time point was calculated. For studies in which the LBN group was compared to timolol maleate 0.5% or latanoprost 0.005%, the differences in the IOP-lowering effect between groups were computed. Then, the standardized mean difference (SMD) of each study was derived by dividing the mean difference by the standard deviation to ensure that the difference was on the same scale. Then, the SMDs of the included studies were pooled to derive the overall differences at each time point. Forest plots were used to illustrate the point estimates of SMDs with a 95% confidence interval (CI). Moreover, the I2 statistic was used to assess heterogeneity across each trial. The I2 statistic reveals the percentage of variation between studies that is due to heterogeneity rather than chance or sampling error. An outcome of over 75% indicates considerable heterogeneity. Publication bias was determined using funnel plots and Egger’s test.

3. Results

3.1. Search Results

Figure 1 shows the PRISMA flow diagram of study screening. An initial search yielded 185 citations. After eliminating duplicated records (n = 46), 139 studies remained. Then, we excluded non-relevant studies (n = 68). Studies categorized as reviews, meta-analyses, and conference abstracts were also excluded (n = 56). We further excluded three animal studies, two papers not written in English, and one study in which LBN 0.024% was not used in glaucoma patients. Finally, nine studies were included in our meta-analysis.

3.2. Characteristics of Included Studies

Table 1 summarizes the characteristics of the nine studies. Seven studies were from the USA or Europe, and two were from Asia. Most of the studies were RCTs, and three studies were retrospective chart reviews. The study conducted by Weinreb et al. published in 2018 [14] was a pooled analysis of the LUNAR and APOLLO studies; thus, we only adopted data from the safety extension phase to avoid repetition. In total, 2389 patients were included in this meta-analysis with an average age of 63.2 years old.

3.3. Outcome Assessment

Table 2 shows the baseline and post-treatment IOP at each time point (1 week, 2 weeks, 6 weeks, 3 months, 6 months, 9 months, and 12 months) in the included studies. Seven studies had IOP data up to 6 weeks after treatment, and only one study had a follow-up time reaching 12 months. Four studies had one arm of LBN 0.024%, three studies (LUNAR, APOLLO, and CONSTELLATION) compared LBN 0.024% vs. timolol maleate 0.5%, one study (VOYAGER) compared LBN 0.024% vs. latanoprost 0.005%, and one study compared the effectiveness of all three drugs.
Figure 2 illustrates the SMDs of IOP between the post-treatment time points and baseline. All studies reported a significant reduction in IOP at every time point after LBN treatment. Subgroup analysis according to each time point revealed a significant pooled IOP reduction with LBN from 2 weeks to 12 months (SMD was −3.926 at 2 weeks, −2.429 at 6 weeks, −3.110 at 3 months, −2.081 at 6 months, −1.759 at 9 months, and −2.457 at 12 months).
Figure 3 compares the IOP-reducing effect between LBN 0.024% and timolol maleate 0.5% at 2 weeks, 6 weeks, and 3 months. At these three time points, LBN significantly reduced IOP more than timolol. The SMDs were −0.61 (95% confidence interval (CI): −0.95 to −0.27), −0.66 (95% CI: −0.81 to −0.52), and −0.98 (95% CI: −1.36 to −0.61), respectively.
Figure 4 compares the IOP reduction between LBN 0.024% and latanoprost 0.005% at 1 week, 2 weeks, 6 weeks, and 3 months post-treatment. After pooling the results of different time points, the overall SMD was statistically significant with a value of −0.599 (95% CI: −1.022 to −0.177).
Subsequently, we recorded the adverse events in each study to assess the safety of LBN 0.024%. The three most common ocular side effects were conjunctival hyperemia, eye irritation, and dry eye, as shown in Table 3. The percentage of patients who had at least one adverse effect ranged from 8.7% to 50.8%. However, no serious adverse effects threatening vital signs or permanently decreasing vision were reported.

3.4. Heterogeneity and Publication Bias

Regarding the IOP reduction achieved with LBN, the analyses showed high heterogeneity (all I2 > 93%). When comparing the IOP-reduction effects between LBN and timolol or latanoprost, we still found high heterogeneity among the included studies (all I2 > 80%).
Figure 5 shows the funnel plots for calculating publication bias in studies analyzing the IOP reduction obtained with LBN, comparing IOP reduction between LBN and timolol, and comparing IOP reduction between LBN and latanoprost. The graphics were generally symmetric and were found to be nonsignificant based on Egger’s test (p values were 0.13, 0.44 and 0.09, respectively), revealing no significant publication bias in any of the included studies.

4. Discussion

This meta-analysis included nine studies (2389 patients with open-angle glaucoma and ocular hypertension) focused on the IOP-reducing efficacy of LBN 0.024%. LBN 0.024% significantly decreased IOP at all time points from 2 weeks to 12 months. Moreover, compared with timolol maleate 0.5% and latanoprost 0.005%, LBN 0.024% was significantly superior in reducing IOP (LBN vs. timolol: SMD −0.61 at 2 weeks, −0.66 at 6 weeks, and −0.98 at 3 months; LBN vs. latanoprost: SMD −0.599 pooled over each time point).
LBN breaks down into two active components, latanoprost and a NO-donating agent, on the ocular surface which can increase aqueous humor outflow through the uveoscleral and trabecular routes, respectively [18,19]. LBN has an additional NO-donating property, thus explaining why LBN reduces IOP more than latanoprost and timolol.
NO and its second messenger, cyclic guanosine monophosphate (cGMP), mediate smooth muscle relaxation and vasodilation [20]. Similarly, NO exerts action on trabecular meshwork cells, which are highly contractile, and reduces their cell volume [21]. NO may also relax the inner wall of Schlemm’s canal and disrupt intercellular adherens junctions, thus enhancing the outflow from the trabecular route [22,23]. In in vitro studies and animal studies, LBN demonstrated a superior hypotensive effect compared to latanoprost [6,24]. Our meta-analysis, which was comprehensive, enrolling clinical trials and real-world studies in humans regarding LBN to date, found that LBN has a better IOP-lowering effect than latanoprost 0.005% and timolol maleate 0.5%. Our findings were compatible with those in a previous meta-analysis conducted by Harasymowycz et al. [25] evaluating the short-term treatment efficacy at 3 months. The strength of our study is the longer study period (up to 12 months). Therefore, we summarize the mid-term efficacy of LBN 0.024%. Another strength of our study is that we analyzed the IOP-lowering effect at various time points. We noticed that after 2 weeks of treatment, the level of the IOP reduction was stable to the end of follow-up (12 months) without prominent fluctuation. Further long-term studies are needed to understand the long-term benefit of LBN 0.024%.
Another strength of our study is that the patients we enrolled were naive to glaucoma eye drops or had experienced a washout period; thus, we could derive the pure effect of LBN 0.024%. However, in most real-world practice, LBN 0.024% is added to the patient’s regimen or the patient is switched to LBN. Therefore, further real-world studies are warranted to assess the IOP-lowering effect in patients with add-on or switching to LBN 0.024%.
One limitation of our analyses is the high heterogeneity among the included studies. The heterogeneity might originate from diversity in the study population, such as demographics, the severity of glaucoma, baseline IOP, and compliance. Fortunately, despite the heterogeneity, all of the studies demonstrated a tendency towards a significant IOP reduction, thereby providing strong evidence of the effectiveness of LBN 0.024%. Another limitation is that only nine studies were included in our meta-analysis. Treatment effects of LBN 0.024% and the other two drugs were compared within a short-term, three-month duration. With the approval and commercialization of LBN 0.024%, more studies will be conducted to evaluate the long-term effectiveness.
We have found that LBN 0.024% was generally safe and had only minor side effects. Given that LBN 0.024% is among the first NO-donating compounds for topical ophthalmic use, we should continue monitoring the possibility of long-term side effects. Furthermore, previous studies have suggested that NO enhances ocular perfusion and thus possesses a neuroprotective function [26,27]. Due to limited data at present, we cannot conduct a meta-analysis regarding the neuroprotective effects. Further research will be warranted to evaluate the impact of LBN 0.024% on the preservation of the nerve fiber layer or visual field, thus providing profound knowledge of LBN 0.024%.

5. Conclusions

Our study used a meta-analysis to investigate the IOP-lowering performance of LBN 0.024%. According to a pooled analysis of 2389 patients with OAG or OHT from nine trials, we found that LBN 0.024% could significantly reduce IOP and was more effective than timolol maleate 0.5% and latanoprost 0.005% during the follow-up period of three months. There were no serious adverse effects related to LBN.

Author Contributions

Conceptualization, T.-C.L. and Y.-Y.C.; methodology, Y.-Y.C., M.-C.H. and P.C.; formal analysis, T.-C.L.; investigation, Y.-Y.C.; writing—original draft preparation, T.-C.L.; writing—review and editing, Y.-Y.C.; supervision, Y.-Y.C. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Taipei Veterans General Hospital and Taichung Veterans General Hospital (grant number TCVGH-1116901B).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data analyzed in this study were a re-analysis of existing data which are openly available at locations cited in the reference section.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Heijl, A.; Leske, M.C.; Bengtsson, B.; Hyman, L.; Bengtsson, B.; Hussein, M. Reduction of intraocular pressure and glaucoma progression: Results from the early manifest glaucoma trial. Arch. Ophthalmol. 2002, 120, 1268–1279. [Google Scholar] [CrossRef] [PubMed]
  2. Leske, M.C.; Heijl, A.; Hussein, M.; Bengtsson, B.; Hyman, L.; Komaroff, E. Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial. Arch. Ophthalmol. 2003, 121, 48–56. [Google Scholar] [CrossRef]
  3. Prum, B.E., Jr.; Lim, M.C.; Mansberger, S.L.; Stein, J.D.; Moroi, S.E.; Gedde, S.J.; Herndon, L.W., Jr.; Rosenberg, L.F.; Williams, R.D. Primary open-angle glaucoma suspect preferred practice pattern® guidelines. Ophthalmology 2016, 123, P112–P151. [Google Scholar] [CrossRef]
  4. Li, T.; Lindsley, K.; Rouse, B.; Hong, H.; Shi, Q.; Friedman, D.S.; Wormald, R.; Dickersin, K. Comparative effectiveness of first-line medications for primary open-angle glaucoma: A systematic review and network meta-analysis. Ophthalmology 2016, 123, 129–140. [Google Scholar] [CrossRef] [Green Version]
  5. Garway-Heath, D.F.; Crabb, D.P.; Bunce, C.; Lascaratos, G.; Amalfitano, F.; Anand, N.; Azuara-Blanco, A.; Bourne, R.R.; Broadway, D.C.; Cunliffe, I.A.; et al. Latanoprost for open-angle glaucoma (ukgts): A randomised, multicentre, placebo-controlled trial. Lancet 2015, 385, 1295–1304. [Google Scholar] [CrossRef] [Green Version]
  6. Krauss, A.H.; Impagnatiello, F.; Toris, C.B.; Gale, D.C.; Prasanna, G.; Borghi, V.; Chiroli, V.; Chong, W.K.; Carreiro, S.T.; Ongini, E. Ocular hypotensive activity of bol-303259-x, a nitric oxide donating prostaglandin f2α agonist, in preclinical models. Exp. Eye Res. 2011, 93, 250–255. [Google Scholar] [CrossRef]
  7. Kaufman, P.L. Latanoprostene bunod ophthalmic solution 0.024% for iop lowering in glaucoma and ocular hypertension. Expert Opin. Pharmacother. 2017, 18, 433–444. [Google Scholar] [CrossRef] [Green Version]
  8. Cavet, M.E.; Vittitow, J.L.; Impagnatiello, F.; Ongini, E.; Bastia, E. Nitric oxide (no): An emerging target for the treatment of glaucoma. Investig. Ophthalmol. Vis. Sci. 2014, 55, 5005–5015. [Google Scholar] [CrossRef] [Green Version]
  9. Weinreb, R.N.; Ong, T.; Scassellati Sforzolini, B.; Vittitow, J.L.; Singh, K.; Kaufman, P.L. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: The voyager study. Br. J. Ophthalmol. 2015, 99, 738–745. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Medeiros, F.A.; Martin, K.R.; Peace, J.; Scassellati Sforzolini, B.; Vittitow, J.L.; Weinreb, R.N. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: The lunar study. Am. J. Ophthalmol. 2016, 168, 250–259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Weinreb, R.N.; Scassellati Sforzolini, B.; Vittitow, J.; Liebmann, J. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: The apollo study. Ophthalmology 2016, 123, 965–973. [Google Scholar] [CrossRef] [Green Version]
  12. Liu, J.H.K.; Slight, J.R.; Vittitow, J.L.; Scassellati Sforzolini, B.; Weinreb, R.N. Efficacy of latanoprostene bunod 0.024% compared with timolol 0.5% in lowering intraocular pressure over 24 hours. Am. J. Ophthalmol. 2016, 169, 249–257. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Kawase, K.; Vittitow, J.L.; Weinreb, R.N.; Araie, M. Long-term safety and efficacy of latanoprostene bunod 0.024% in japanese subjects with open-angle glaucoma or ocular hypertension: The jupiter study. Adv. Ther. 2016, 33, 1612–1627. [Google Scholar] [CrossRef] [Green Version]
  14. Weinreb, R.N.; Liebmann, J.M.; Martin, K.R.; Kaufman, P.L.; Vittitow, J.L. Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: Pooled phase 3 study findings. J. Glaucoma 2018, 27, 7–15. [Google Scholar] [CrossRef] [PubMed]
  15. Okeke, C.O.; Burstein, E.S.; Trubnik, V.; Deom, J.E.; Cooper, M.S.; Brinkley, D.A.; Thimons, J.J.; Kabiri, A.J.; Gelb, K.M. Retrospective chart review on real-world use of latanoprostene bunod 0.024% in treatment-naïve patients with open-angle glaucoma. Ophthalmol. Ther. 2020, 9, 1041–1053. [Google Scholar] [CrossRef] [PubMed]
  16. Wang, Y.; Liao, Y.; Nie, X. Comparative evaluation of latanoprostene bunod, timolol maleate, and latanoprost ophthalmic solutions to assess their safety and efficacy in lowering intraocular pressure for the management of open-angle glaucoma. Clinics 2020, 75, e1874. [Google Scholar] [CrossRef]
  17. Radell, J.E.; Sharma, H.K.; Auyeung, K.L.; Paul, M.E.; Gagliuso, D.J.; Chadha, N.; Tsai, J.C.; Serle, J.B. Two-year experience with latanoprostene bunod in clinical practice. J. Glaucoma 2021, 30, 776–780. [Google Scholar] [CrossRef] [PubMed]
  18. MacIver, S.; Stout, N.; Ricci, O. New considerations for the clinical efficacy of old and new topical glaucoma medications. Clin. Exp. Optom. 2021, 104, 350–366. [Google Scholar] [CrossRef]
  19. Cvenkel, B.; Kolko, M. Current medical therapy and future trends in the management of glaucoma treatment. J. Ophthalmol. 2020, 2020, 6138132. [Google Scholar] [CrossRef]
  20. Arnal, J.F.; Dinh-Xuan, A.T.; Pueyo, M.; Darblade, B.; Rami, J. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell. Mol. Life Sci. 1999, 55, 1078–1087. [Google Scholar] [CrossRef]
  21. Dismuke, W.M.; Mbadugha, C.C.; Ellis, D.Z. No-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the bkca ion channel. Am. J. Physiol. Cell Physiol. 2008, 294, C1378–C1386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Schneemann, A.; Dijkstra, B.G.; van den Berg, T.J.; Kamphuis, W.; Hoyng, P.F. Nitric oxide/guanylate cyclase pathways and flow in anterior segment perfusion. Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2002, 240, 936–941. [Google Scholar] [CrossRef] [PubMed]
  23. Heimark, R.L.; Kaochar, S.; Stamer, W.D. Human schlemm’s canal cells express the endothelial adherens proteins, ve-cadherin and pecam-1. Curr. Eye Res. 2002, 25, 299–308. [Google Scholar] [CrossRef] [PubMed]
  24. Cavet, M.E.; Vollmer, T.R.; Harrington, K.L.; VanDerMeid, K.; Richardson, M.E. Regulation of endothelin-1-induced trabecular meshwork cell contractility by latanoprostene bunod. Investig. Ophthalmol. Vis. Sci. 2015, 56, 4108–4116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Harasymowycz, P.; Royer, C.; Cui, A.X.; Barbeau, M.; Jobin-Gervais, K.; Mathurin, K.; Lachaine, J.; Beauchemin, C. Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: A systematic literature review and a network meta-analysis. Br. J. Ophthalmol. 2022, 106, 640–647. [Google Scholar] [CrossRef]
  26. Mao, Y.J.; Wu, J.B.; Yang, Z.Q.; Zhang, Y.H.; Huang, Z.J. Nitric oxide donating anti-glaucoma drugs: Advances and prospects. Chin. J. Nat. Med. 2020, 18, 275–283. [Google Scholar] [CrossRef]
  27. Matsou, A.; Anastasopoulos, E. Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma. Expert Opin. Investig. Drugs 2018, 27, 777–785. [Google Scholar] [CrossRef] [PubMed]
Jcm 11 04325 g001 550
Figure 1. Study retrieval process according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.
Figure 1. Study retrieval process according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.
Jcm 11 04325 g001
Jcm 11 04325 g002 550
Figure 2. The overall effect of latanoprostene bunod on intraocular pressure.
Figure 2. The overall effect of latanoprostene bunod on intraocular pressure.
Jcm 11 04325 g002
Jcm 11 04325 g003 550
Figure 3. Comparison of IOP-lowering effect between latanoprostene bunod 0.024% and timolol maleate 0.5%.
Figure 3. Comparison of IOP-lowering effect between latanoprostene bunod 0.024% and timolol maleate 0.5%.
Jcm 11 04325 g003
Jcm 11 04325 g004 550
Figure 4. Comparison of IOP-lowering effects of latanoprostene bunod 0.024% and latanoprost 0.005%.
Figure 4. Comparison of IOP-lowering effects of latanoprostene bunod 0.024% and latanoprost 0.005%.
Jcm 11 04325 g004
Jcm 11 04325 g005 550
Figure 5. Funnel plots evaluating the publication biases regarding the IOP-lowering impacts of (a) LBN 0.024%; (b) the comparison between LBN 0.024% and timolol maleate 0.5%; and (c) the comparison between LBN 0.024% and latanoprost 0.005%. Circles represented studies.
Figure 5. Funnel plots evaluating the publication biases regarding the IOP-lowering impacts of (a) LBN 0.024%; (b) the comparison between LBN 0.024% and timolol maleate 0.5%; and (c) the comparison between LBN 0.024% and latanoprost 0.005%. Circles represented studies.
Jcm 11 04325 g005
Table
Table 1. Demographic characteritics of patients in studies included in meta-analysis.
Table 1. Demographic characteritics of patients in studies included in meta-analysis.
First AuthorYearCountryStudy DesignDiagnosisGroupsNum of ptsNum of Eyes Age (Mean ± SD)Male, n (%)
Weinreb (VOYAGER) [9]2015USA, Europe Multicenter RCTPOAG, OHTLBN838360.8 ± 11.4726 (31.3)
Latanoprost828261.2 ± 11.9229 (35.4)
Medeiros (LUNAR) [10]2016USA, Europe Multicenter RCTPOAG, OHTLBN25927865.0 ± 9.77116 (41.7)
Timolol12813664.1 ± 9.7157 (41.9)
Weinreb (APOLLO) [11]2016USA, EuropeMulticenter RCTPOAG, OHTLBN28428464.7 ± 10.3118 (41.5)
Timolol13313363.1 ± 11.256 (42.1)
Liu (CONSTELLATION) [12]2016USAProspective, open-label, RCTPOAG, OHTLBN252560.3 ± 10.67(28)
Timolol252560.3 ± 10.67(28)
Kawase (JUPITER) [13]2016Japansingle-arm, multicenter, open-label, clinical studyOAG, OHTLBN13013062.5 ± 18.956(43.1)
Weinreb (Pooled) [14]2018USA, EuropePooled analysis of APOLLO and LUNARPOAG, OHTLBN56256264.9 ± 10.04234 (41.6)
Timolol *26926963.7 ± 10.47113 (42.0)
Okeke [15]2020USAMulti-center retrospectivePOAG, LTG, othersLBN656559.3 ± 14.430 (46.2)
Wang [16]2020ChinaRetrospective POAG, OHTLatanoprost104NR58.42 ± 6.1255 (53)
LBN94NR57.65 ± 6.0149 (52)
Timolol115NR57.99 ± 6.4453 (46)
Radell [17]2021USASingle center retrospective POAG, LTG, othersLBN5610268.8 ± 12.428 (50)
Num number, pts patients, SD Standard deviation, NR Not-reported, RCT Randomized controlled trial, POAG Primary open-angle glaucoma, OHT Ocular hypertension, LTG low tension glaucoma, LBN Latanoprostene bunod. * crossover to LBN after 12 weeks.
Table
Table 2. IOP at baseline and post-treatment visits.
Table 2. IOP at baseline and post-treatment visits.
Post-Treatment IOP
StudyGroupsBaseline IOP (Mean ± SD)1 Week2 Weeks6 Weeks12 Weeks6 Months9 Months12 Months
Weinreb (VOYAGER), 2015 [9]LBN26.01 ± 1.6717.7417.1517.01NRNRNRNR
Latanoprost26.15 ± 1.7918.8618.4318.38NRNRNRNR
Medeiros (LUNAR), 2016 [10]LBN26.6 ± 2.39NR18.618.218.1NRNRNR
Timolol26.4 ± 2.30NR19.219.119.3NRNRNR
Weinreb (APOLLO), 2016 [11]LBN26.7 ± 2.5NR18.218.118.1NRNRNR
Timolol26.5 ± 2.4NR19.519.319.4NRNRNR
Liu (CONSTELLATION), 2016 [12]LBN21.6 ± 2.8NRNR17.6 ± 2.5NRNRNRNR
Timolol21.6 ± 2.8NRNR18.9 ± 2.4NRNRNRNR
Kawase (JUPITER), 2016 [13]LBN19.6 ± 2.9NRNR15.3 ± 3.014.814.714.414.7
Weinreb (Pooled), 2018 [14]LBN *26.7 ± 2.43NANANANA18.1 ± 2.918.2 ± 3.317.9 ± 3.0
Okeke, 2020 [15]LBN21.7 ± 5.9NRNR14.7 ± 4.1NR14.4 ± 3.2NRNR
Wang, 2020 [16]Latanoprost24.13 ± 1.12NRNRNR19.45 ± 1.01NRNRNR
LBN23.98 ± 1.22NRNRNR17.45 ± 1.89NRNRNR
Timolol24.39 ± 1.65NRNRNR19.68 ± 1.08NRNRNR
Radell, 2021 [17]LBN16.2 ± 4.3NRNR14.0 ± 3.6NRNR13.7 ± 3.8NR
IOP Intraocular pressure, SD Standard deviation, w week, m month, LBN Latanoprostene bunod, NR Not-reported, NA Not-applicable. * Extension phases (start from month 3).
Table
Table 3. Treatment-related ocular adverse effects in studies included in meta-analysis.
Table 3. Treatment-related ocular adverse effects in studies included in meta-analysis.
StudyGroupsNum of Eyes≥1 AE, n (%)Types of Complication (%)
Weinreb(VOYAGER), 2015 [9]LBN8320 (24.1)Ocular hyperaemia (2.4), Conjunctival hyperaemia (4.8), Eye irritation (3.6), Punctate keratitis (2.4), Dry eye (2.4), Photophobia (2.4), Instillation site pain(12)
Latanoprost8210 (12.2)Ocular hyperaemia (8.5), Punctate keratitis (1.2), Instillation site pain(6.1)
Medeiros(LUNAR), 2016 [10]LBN27766 (23.8)Conjunctival hyperemia(9), Eye irritation (7.2), Eye pain (5.8), Ocular hyperemia (2.5), Vision blurred (1.8), Eye pruritis (1.4), Dry eye (1.1), Punctate keratitis (1.1), Foreign body sensation (1.1), Instillation site pain(1.4)
Timolol13518 (13.3)Conjunctival hyperemia(0.7), Eye irritation (4.4), Eye pain (3.7), Ocular hyperemia (0.7), Vision blurred (2.2), Eye pruritis (0.7), Dry eye (0.7)
Weinreb(APOLLO), 2016 [11]LBN28338 (13.4)Eye irritation (3.9), Conjunctival hyperemia (2.8), Eye pain (1.4), Dry eye (1.1), Foreign body sensation (1.1), Instillation site pain (1.1)
Timolol13516 (11.9)Eye irritation (2.2), Conjunctival hyperemia (1.5), Eye pain (2.2), Dry eye (0.7), Instillation site pain (1.5)
Liu, 2016 [12]LBN232(8.7)Punctate keratitis (4.3)
Instillation site erythema (4.3)
Timolol234(17.4)Punctate keratitis (13), Instillation site irritation (4.3)
Kawase (JUPITER), 2016 [13]LBN13076 (58.5)conjunctival hyperemia (17.7), growth of eyelashes (16.2 ), eye irritation (11.5), eye pain (10 ), Iris hyperpigmentation(3.8), Blepharal pigmentation(3.1), Blepharitis (2.3), Eye pruritus(2.3), Asthenopia(2.3), Conjunctival hemorrhage (1.5), Punctate keratitis(2.3), Trichiasis(2.3), Cataract(0.8), Hordeolum(0.8), Visual impairment (0.8), Vitreous floaters (0.8), Foreign body sensation(1.5)
Weinreb (Pooled), 2018 [14]LBN(LBN + Timolol cross over to LBN)811175 (21.6)Conjunctival hyperemia(5.9), Eye irritation (4.6), Eye pain (3.6), Ocular hyperemia (2), Instillation site pain (2)
Timolol 27134 (12.5)Conjunctival hyperemia(1.1), Eye irritation (2.6), Eye pain (2.2), Ocular hyperemia (0.7), Instillation site pain (1.8)
Okeke, 2020 [15]LBN6533 (50.8)Blurred vision (15.4), Dryness (12.3), Irritation(7.7), Itching (7.7), Light sensitivity (7.7), Burning (6.2), Eye pain (4.6), Tearing (4.6), Change in vision (3.1), Keratitis (3.1), Macular degeneration (3.1)
Wang, 2020 [16]Latanoprost104NREye irritation (4), Dry eye(2), Eye pain(3), Conjunctival hyperemia(4), Foreign body sensation(3)
LBN94NREye irritation (4), Dry eye(2), Eye pain(3), Conjunctival hyperemia(3), Foreign body sensation(2)
Timolol115NREye irritation (2), Dry eye(1), Eye pain(1), Conjunctival hyperemia(1), Foreign body sensation(1)
Radell, 2021 [17]LBN568(14)pain, itching (14)
Num number, AE treatment-related ocular adverse effects, LBN Latanoprostene Bunod.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lo, T.-C.; Chen, Y.-Y.; Hung, M.-C.; Chou, P. Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis. J. Clin. Med. 2022, 11, 4325. https://doi.org/10.3390/jcm11154325

AMA Style

Lo T-C, Chen Y-Y, Hung M-C, Chou P. Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis. Journal of Clinical Medicine. 2022; 11(15):4325. https://doi.org/10.3390/jcm11154325

Chicago/Turabian Style

Lo, Tzu-Chen, Yu-Yen Chen, Man-Chen Hung, and Pesus Chou. 2022. "Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis" Journal of Clinical Medicine 11, no. 15: 4325. https://doi.org/10.3390/jcm11154325

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop